Integra LifeSciences (NASDAQ:IART) Sets New 1-Year Low After Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price hit a new 52-week low during trading on Friday after Wells Fargo & Company lowered their price target on the stock from $13.00 to $12.00. Wells Fargo & Company currently has an equal weight rating on the stock. Integra LifeSciences traded as low as $10.60 and last traded at $11.33, with a volume of 1253512 shares. The stock had previously closed at $11.59.

Several other equities research analysts also recently commented on the company. JPMorgan Chase & Co. upped their target price on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Truist Financial reaffirmed a “hold” rating and set a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Citigroup reduced their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $14.80.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q4 results: adjusted EPS of $0.83 topped consensus ($0.79) and revenue of $434.9M beat estimates — a near-term fundamental positive that likely supported buying. Integra Surprises With Q4 Sales
• Positive Sentiment: Management highlighted operational progress and a simplified operating model expected to deliver $25–$30M of savings in 2026, underpinning margin improvement expectations. Press Release (GlobeNewswire)
• Positive Sentiment: Core Codman Specialty Surgical segment showed organic growth (neurosurgery, ENT, instruments, strong international sales), offsetting weakness elsewhere and supporting recurring revenue quality. Segment Details
• Neutral Sentiment: Analyst/editor pieces highlight momentum metrics and style scores (useful for some investors) but are not new company-specific catalysts. Zacks Momentum Article
• Neutral Sentiment: Earnings call/transcripts and slide deck are available for deeper read — useful for investors who want management color on remediation, tariffs and execution. Earnings Call Transcript
• Negative Sentiment: Guidance mixed: FY-2026 adjusted EPS of $2.30–$2.40 and revenue guidance imply modest growth, but Q1 EPS guidance ($0.37–$0.45) is below consensus — a near-term headwind for sentiment. Guidance Details
• Negative Sentiment: Legacy issues: the company recorded a $511M goodwill impairment in 2025 and reported a GAAP net loss for the year; leverage remains elevated (net debt ~ $1.6B, ~4.5x leverage), which raises capital-allocation and downside risk concerns. Quiver / Results Summary
• Negative Sentiment: Analyst action: Wells Fargo lowered its price target from $13 to $12 and set an “equal weight” rating, which can cap near-term upside. Wells Fargo PT Cut (Benzinga)

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of IART. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth $25,000. GAMMA Investing LLC raised its stake in shares of Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 913 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences in the 2nd quarter valued at approximately $73,000. Finally, EMC Capital Management acquired a new position in Integra LifeSciences in the second quarter worth approximately $75,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The stock has a market cap of $886.39 million, a P/E ratio of -1.69 and a beta of 1.04. The firm’s 50-day moving average is $11.96 and its two-hundred day moving average is $13.19.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.28%. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.